Neupane Khaga R, McCorkle J Robert, Kopper Timothy J, Lakes Jourdan E, Aryal Surya P, Abdullah Masud, Snell Aaron A, Gensel John C, Kolesar Jill, Richards Christopher I
Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40508, United States.
ACS Omega. 2021 Jan 26;6(5):3847-3857. doi: 10.1021/acsomega.0c05632. eCollection 2021 Feb 9.
Macrophages, one of the most important phagocytic cells of the immune system, are highly plastic and are known to exhibit diverse roles under different pathological conditions. The ability to repolarize macrophages from pro-inflammatory (M1) to anti-inflammatory (M2) or offers a promising therapeutic approach for treating various diseases such as traumatic injury and cancer. Herein, it is demonstrated that macrophage-engineered vesicles (MEVs) generated by disruption of macrophage cellular membranes can be used as nanocarriers capable of reprogramming macrophages and microglia toward either pro- or anti-inflammatory phenotypes. MEVs can be produced at high yields and easily loaded with diagnostic molecules or chemotherapeutics and delivered to both macrophages and cancer cells and . Overall, MEVs show promise as potential delivery vehicles for both therapeutics and their ability to controllably modulate macrophage/microglia inflammatory phenotypes.
巨噬细胞是免疫系统中最重要的吞噬细胞之一，具有高度可塑性，已知在不同病理条件下发挥多种作用。将巨噬细胞从促炎（M1）重极化至抗炎（M2）的能力为治疗创伤性损伤和癌症等各种疾病提供了一种有前景的治疗方法。在此证明，通过破坏巨噬细胞膜产生的巨噬细胞工程化囊泡（MEV）可用作纳米载体，能够将巨噬细胞和小胶质细胞重编程为促炎或抗炎表型。MEV可以高产率生产，易于装载诊断分子或化疗药物，并递送至巨噬细胞和癌细胞。总体而言，MEV作为治疗药物的潜在递送载体及其可控调节巨噬细胞/小胶质细胞炎症表型的能力显示出前景。
